Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis
North America peptide-based gastrointestinal disorders therapeutics market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market.
Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients